SCHEMBL347688

SCHEMBL347688

O=[C]Cc1c[nH]c2ccccc12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.62
KMT2A Q03164 6/20 0.62
MAPT P10636 4/20 0.62
CYP3A4 P08684 3/20 0.62
AHR P35869 1/20 0.62
GPR84 Q9NQS5 1/20 0.62
TDP1 Q9NUW8 1/20 0.62
HTR2A P28223 4/20 0.59
CYP2D6 P10635 3/20 0.59
HTR2C P28335 3/20 0.59
HTR1D P28221 2/20 0.59
HTR1B P28222 2/20 0.59
HTR7 P34969 2/20 0.59
HTR6 P50406 2/20 0.59
MPO P05164 1/20 0.59
CYP1A2 P05177 1/20 0.59
CYP2A6 P11509 1/20 0.59
NFKB1 P19838 1/20 0.59
CTSK P43235 1/20 0.59
CYP2A13 Q16696 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1308758 0.85 MEN1 (0.62) MEN1KMT2AMAPTCYP3A4AHR
SCHEMBL349109 0.82 SLC6A4 (0.58) MEN1KMT2AMAPTCYP3A4AHR
SCHEMBL6805445 0.82 HTR2A (0.57) MEN1KMT2AMAPTCYP3A4AHR
SCHEMBL348936 0.81 HTR2A (0.61) MEN1KMT2AMAPTCYP3A4AHR
SCHEMBL29521038 0.81 MEN1 (0.62) MEN1KMT2AMAPTCYP3A4AHR
SCHEMBL3225554 0.81 MEN1 (0.62) MEN1KMT2AMAPTCYP3A4AHR
SCHEMBL149254 0.81 MEN1 (0.62) MEN1KMT2AMAPTCYP3A4AHR
Tryptamine SCHEMBL27810114 0.80 HTR2A (0.86) MEN1KMT2AMAPTCYP3A4AHR
SCHEMBL6524121 0.78 MEN1 (0.69) MEN1KMT2AMAPTCYP3A4AHR
SCHEMBL29413080 0.78 MEN1 (0.69) MEN1KMT2AMAPTCYP3A4AHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 364 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3801489-A1 ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISORDERS Flagship Pioneering Innovations V, Inc. (US) 2021-04-14 EP claimed
WO-2020245629-A1 MIXTURES AND COMPOSITIONS OF FLUENSULFONE AND AUXIN, AND USES THEREOF ADAMA MAKHTESHIM LTD> (IL) 2020-12-10 WO claimed
US-10654838-B2 Aminopyridine compounds useful as inhibitors of protein prenylation INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2020-05-19 US claimed
EP-3204380-B1 NOVEL AMINOPYRIDINE COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN PRENYLATION INST NAT SANTE RECH MED (FR) 2019-08-07 EP claimed
CN-107513081-A The acetyl glutamy Glucosamine propane of 2,2 2 indoles 3, it is synthesized, anti-inflammatory activity and application 首都医科大学 2017-12-26 CN claimed
US-20170305892-A1 NOVEL AMINOPYRIDINE COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN PRENYLATION INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2017-10-26 US claimed
EP-3204380-A1 NOVEL AMINOPYRIDINE COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN PRENYLATION Institut National de la Santé et de la Recherche Médicale (FR) 2017-08-16 EP claimed
CN-107001315-A It can be used as the novel aminopyridine compound of the inhibitor of protein prenylation 国家健康与医学研究院 2017-08-01 CN claimed
CN-106946910-A Parallel indoles acetyl derivatives of a kind of pyrans and its preparation method and application 上海海洋大学 2017-07-14 CN claimed
CN-106537145-A Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment 麦特博隆股份有限公司 2017-03-22 CN claimed
EP-0480918-A1 REDUCED SIZE LHRH ANALOGS ABBOTT LABORATORIES (US) 1992-04-22 EP claimed
US-5068222-A Polypeptides for treatment of cancer IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1991-11-26 US claimed
EP-0480918-A4 REDUCED SIZE LHRH ANALOGS. ABBOTT LAB (US) 1991-06-04 EP claimed
EP-0417454-A2 Reduced size LHRH analogs ABBOTT LABORATORIES (US) 1991-03-20 EP claimed
WO-1989007451-A1 REDUCED SIZE LHRH ANALOGS ABBOTT LABORATORIES (US) 1989-08-24 WO claimed
EP-0328089-A2 Reduced size LHRH analogs ABBOTT LABORATORIES (US) 1989-08-16 EP claimed
EP-0315367-A2 Polypeptides IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1989-05-10 EP claimed
US-4563464-A 2-Azabicyclo(2.2.2)octane derivatives and their use as immunosuppressive agents RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 1986-01-07 US claimed
EP-0132964-A2 2-Azabicyclo[2.2.2]octane derivatives RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) 1985-02-13 EP claimed
US-3971736-A HEXA- AND HEPTA-PEPTIDES, ANTIINFLAMMATORY, ANTIULCER, ANTIARTHRITIC MERCK & CO., INC. (US) 1976-07-27 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170305892-A1 NOVEL AMINOPYRIDINE COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN PRENYLATION RCE1, PTAR1, CDK2AP1 MEN1 2611/4885KMT2A 3937/4885MAPT 3835/4885
US-10654838-B2 Aminopyridine compounds useful as inhibitors of protein prenylation RCE1, PTAR1, CDK2AP1 MEN1 2138/4885KMT2A 3735/4885MAPT 3654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.